Table 1.
Demographics and Clinical Characteristics of the Patients
| Characteristic | Preoperative TNF-α inhibitors (+) (n=45) |
With POT (n=20) |
Without POT (n=25) |
p-value |
|---|---|---|---|---|
| Male sex | 28 (62.2) | 14 (70.0) | 14 (56.0) | 0.336 |
| Age at diagnosis, yr | 24.0 (19.0–30.0) | 22.0 (16.3–28.0) | 25.0 (20.5–34.0) | 0.053 |
| Time from diagnosis to surgery, mo | 80.0 (55.0–118.0) | 71.5 (51.5–110.0) | 92.0 (55.0–127.0) | 0.607 |
| Time from diagnosis to the first biologics, mo | 51.0 (31.0–75.0) | 53.5 (32.8–79.0) | 45.0 (29.5–80.0) | 0.508 |
| Age (A) | 0.012 | |||
| A1 (<16 yr) | 5 (11.1) | 5 (25.0) | 0 | |
| A2 (17–40 yr) | 37 (82.2) | 15 (75.0) | 22 (88.0) | |
| A3 (>40 yr) | 3 (6.7) | 0 | 3 (12.0) | |
| Disease extent (L) | 0.663 | |||
| L1 (ileal) | 8 (17.8) | 3 (15.0) | 5 (20.0) | |
| L2 (colonic) | 0 | 0 | 0 | |
| L3 (ileocolonic) | 37 (82.2) | 17 (85.0) | 20 (80.0) | |
| L4 (upper) | 0 | 0 | 0 | |
| Disease characteristics | 0.154 | |||
| B1 (non-stricturing, non-penetrating) | 10 (22.2) | 6 (30.0) | 4 (16.0) | |
| B2 (stricturing) | 12 (26.7) | 7 (35.0) | 5 (20.0) | |
| B3 (penetrating) | 23 (51.1) | 7 (35.0) | 16 (64.0) | |
| Perianal disease | 28 (62.2) | 12 (60.0) | 16 (64.0) | 0.783 |
| Smoking | 0.657 | |||
| Never-smoker | 37 (82.2) | 17 (85.0) | 20 (80.0) | |
| Former smoker | 7 (15.6) | 3 (15.0) | 4 (16.0) | |
| Current smoker | 1 (2.2) | 0 | 1 (4.0) | |
| Smoking after surgery | 0 | 0 | 0 | NA |
| Appendectomy | 5 (11.1) | 3 (15.0) | 2 (8.0) | 0.458 |
| Family history | 2 (4.4) | 0 | 2 (8.0) | 0.196 |
| Height, cm | 168.0 (163.0–172.5) | 167.5 (161.5–169.5) | 170.0 (164.0–173.5) | 0.243 |
| Weight, kg | 53.0 (48.0–61.0) | 51.0 (42.0–61.8) | 55.0 (50.0–61.0) | 0.262 |
| Surgical recurrence | 4 (8.9) | 1 (5.0) | 3 (12.0) | 0.412 |
| Endoscopic recurrence | 14/30 (46.7) | 4/13 (30.8) | 10/17 (58.8) | 0.127 |
| Clinical recurrence | 22 (48.9) | 3 (15.0) | 19 (76.0) | <0.001 |
| Mortality, No. (%) | 1 (2.2)* | 0 | 1 (4.0)* | 0.366 |
| Total number of preoperative biologic agents | 0.241 | |||
| 1 | 31 (68.9) | 16 (80.0) | 15 (60.0) | |
| 2 | 12 (26.7) | 4 (20.0) | 8 (32.0) | |
| 3 | 2 (4.4) | 0 | 2 (8.0) | |
| TNF-α inhibitors just before surgery | 0.540 | |||
| Infliximab | 27 (60.0) | 13 (65.0) | 14 (56.0) | |
| Adalimumab | 18 (40.0) | 7 (35.0) | 11 (44.0) | |
| TNF-α inhibitors just after surgery | - | - | - | |
| Infliximab | 13 (65.0) | |||
| Adalimumab | 7 (35.0) | |||
| Concomitant use of immunomodulators | 31 (68.9) | 16 (80.0) | 15 (60.0) | 0.150 |
Data are presented as number (%), median (IQR), or number/number (%).
TNF, tumor necrosis factor; POT, postoperative TNF-α inhibitors; IQR, interquartile range; NA, data not available for statistical analysis.
*Time from surgery to death, 13 months.